Request a Quote |

Director/PDMR Shareholding - amendment

This is a correction of the announcement 2276R from 7.00 on 18.08.2010. Reason for the correction: the number of shares acquired for each director was incorrect. The corrected version is set out below.

Cyprotex PLC ("Cyprotex" or the "Company")

Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:

 

Name

Title

Price 

Shares acquired

Total interest following dealing

% of total issued share capital

Steve Harris

Chairman 

3.50

707,142

1,507,142

0.67

Anthony Baxter

CEO

3.50

226,285

1,067,685

0.48

John Dootson

CFO

3.50

589,285

589,285

0.26

Katya Tsaioun

CSO

3.50

1,767,857

24,133,006

10.79

Douglas Bates

CMO

3.50

5,303,571

27,668,719

12.37

 

For further information please contact:

Cyprotex PLC

Tel: +44 1625 505 100

Dr. Anthony Baxter, Chief Executive Officer

 

a.baxter@cyprotex.com

 

www.cyprotex.com

 

Singer Capital Markets Ltd

Tel: +44 203 205 7500

Shaun Dobson

 

Claes Spång

 

Financial Dynamics

Tel: +44 207 831 3113

Ben Brewerton

 

Ben Atwell

 

Mo Noonan

 

 

 

 

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Close